# WVE-007

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/wve-007
Canonical HTML page: https://getbiobrief.com/entity/wve-007

## Recent coverage (1 stories)

### Wave's WVE-007 Silences Activin E by 88%, Sustained for 7.5 Months in Phase I
2026-08-04 04:01:27 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Full story: https://getbiobrief.com/story/wave-007-88-percent-activin-e-silencing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.